Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN, April 5 (Reuters) - Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business.